WO2017204688A3 - Système pour obtenir un sérum autologue - Google Patents

Système pour obtenir un sérum autologue Download PDF

Info

Publication number
WO2017204688A3
WO2017204688A3 PCT/RU2017/000330 RU2017000330W WO2017204688A3 WO 2017204688 A3 WO2017204688 A3 WO 2017204688A3 RU 2017000330 W RU2017000330 W RU 2017000330W WO 2017204688 A3 WO2017204688 A3 WO 2017204688A3
Authority
WO
WIPO (PCT)
Prior art keywords
syringe
autologous serum
producing
producing autologous
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2017/000330
Other languages
English (en)
Russian (ru)
Other versions
WO2017204688A2 (fr
Inventor
Артем Витальевич ДЫДЫКИН
Янина Иозавна ЗУЕВА
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2017204688A2 publication Critical patent/WO2017204688A2/fr
Publication of WO2017204688A3 publication Critical patent/WO2017204688A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne la médecine humaine et notamment un système pour obtenir un sérum autologue présentant une teneur élevée en IL-1 RA et en facteurs de croissance, et une teneur réduite en cytokine anti-inflammatoire et d'autres facteurs anti-inflammatoires, et peut être utilisée pour obtenir des préparations de plasma autologue dans différentes variantes utilisées activement en médecine humaine pour traiter un large spectre d'affections. Le résultat de la solution technique proposée consiste à réduire sensiblement la concentration de la cytokine inflammatoire IL-1β ce qui a pour conséquence une meilleure efficacité thérapeutique du sérum autologue concentré. Le système pour obtenir un sérum autologue à teneur plus éleveé en IL-1RA comprend une première seringue, les parois internes de laquelle sont recouvertes d'un sorbant polymérique en phase solide comportant des anticorps monoclonaux contre IL-1β qui y sont fixés, qui comprend des billes de verre ayant un diamètre de 2,5 à 3,5 mm occupant jusqu'à 40 % du volume global de la seringue, et au moins une seringue dont les parois internes sont recouvertes d'un sorbant polymérique en phase solide sur lequel sont fixées des IL-1β humaines, ainsi qu'un raccord stérile réalisé de manière à permettre le transfert du sérum autologue de la seringue avec des anticorps dans la seringue avec des IL-1β humaines.
PCT/RU2017/000330 2016-05-24 2017-05-22 Système pour obtenir un sérum autologue Ceased WO2017204688A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2016120010A RU2617537C1 (ru) 2016-05-24 2016-05-24 Система для получения аутологичной сыворотки
RU2016120010 2016-05-24

Publications (2)

Publication Number Publication Date
WO2017204688A2 WO2017204688A2 (fr) 2017-11-30
WO2017204688A3 true WO2017204688A3 (fr) 2018-03-01

Family

ID=58643279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2017/000330 Ceased WO2017204688A2 (fr) 2016-05-24 2017-05-22 Système pour obtenir un sérum autologue

Country Status (2)

Country Link
RU (1) RU2617537C1 (fr)
WO (1) WO2017204688A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118483410B (zh) * 2024-07-15 2024-10-18 烟台大学 一种免疫检测装置及基于该装置的免疫检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100125236A1 (en) * 2008-11-17 2010-05-20 Christopher Bare Cytokine concentration system
US20140249071A1 (en) * 2013-03-01 2014-09-04 Arthrex, Inc. Enhanced anabolic cytokine production and delivery system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100125236A1 (en) * 2008-11-17 2010-05-20 Christopher Bare Cytokine concentration system
US20140249071A1 (en) * 2013-03-01 2014-09-04 Arthrex, Inc. Enhanced anabolic cytokine production and delivery system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARRETO A. ET AL.: "A method to induce Interleukin-1 Receptor Antagonist Protein from autologous whole blood", CYTOKINE, vol. 81, 16 March 2016 (2016-03-16), pages 137 - 141, XP029465926 *
MAGALON J. ET AL.: "Physico-chemical factors influencing autologous conditioned serum purification", BIORES OPEN ACCESS., vol. 3, no. 1, 1 February 2014 (2014-02-01), pages 35 - 8, XP055260144 *

Also Published As

Publication number Publication date
WO2017204688A2 (fr) 2017-11-30
RU2617537C1 (ru) 2017-04-25

Similar Documents

Publication Publication Date Title
Merten et al. Viral vectors for gene therapy and gene modification approaches
RU2012127380A (ru) Гуманизированные антитела против il-10 для лечения системной красной волчанки (slt)
Meyersburg et al. Immunoadsorption in dermatology
SG10201903474PA (en) New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
FI3353210T3 (fi) Tigit-vasta-aineita ja käyttömenetelmiä
JP2016501013A5 (fr)
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
WO2013088148A3 (fr) Méthode de traitement à l'aide d'un produit à base de lymphocytes t thérapeutiques provenant de donneurs mobilisés
NZ701915A (en) High-concentration monoclonal antibody formulations
EP2186877A3 (fr) Système de concentration de cytokine
IL273841B1 (en) Antibodies targeting cd137 and methods of use thereof
HRP20220088T1 (hr) Dvojno-specifično fixaxfx antitijelo sa zajedničkim lakim lancem
Ghosh et al. Haploidentical stem cell transplantation in DOCK8 deficiency-Successful control of pre-existing severe viremia with a TCRass/CD19-depleted graft and antiviral treatment
CN104789595A (zh) 嵌合抗原受体双阴性t细胞的构建方法
WO2016184394A3 (fr) Photobioréacteur utilisé pour la culture d'algues et système de culture d'algues
WO2017014679A3 (fr) Anticorps monoclonal humanisé spécifique du syndécane-1
JP2015510882A5 (fr)
Abdalla et al. Insight into the emerging role of SARS-CoV-2 nonstructural and accessory proteins in modulation of multiple mechanisms of host innate defense
AU2018286475A8 (en) Non-viral gene delivery agent comprising lipopeptide (LP) compounds
US20160340650A1 (en) Blood derived immune stimulatory compositions
WO2017204688A3 (fr) Système pour obtenir un sérum autologue
RU2016150941A (ru) Способ нанесения покрытия и материалы
Winkler et al. Adoptive transfer of purified donor-b-lymphocytes after allogeneic stem cell transplantation: Results from a phase I/IIa clinical trial
US20160289301A1 (en) Process of cloning and further purification to make a recombinant intravenous immunoglobulin
Younis et al. Effect of infliximab on male fertility: Comment on the article" Fertility in male patients with seronegative spondyloarthropathies treated with infliximab" by Saougou et al., Joint Bone Spine 2013; 80, 34-37

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17803149

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17803149

Country of ref document: EP

Kind code of ref document: A2